{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:58:10Z","timestamp":1780513090314,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.radonc.2023.110057","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T02:15:23Z","timestamp":1702606523000},"page":"110057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-3731","authenticated-orcid":false,"given":"Jacob Y.","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":false,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie F.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-7091","authenticated-orcid":false,"given":"Abraham J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narek","family":"Shaverdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-6246","authenticated-orcid":false,"given":"Daphna Y.","family":"Gelblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-5790","authenticated-orcid":false,"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-3856","authenticated-orcid":false,"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110057_b0005","unstructured":"Key Statistics About Malignant Mesothelioma. American Cancer Society. Last Revised: 9 January 2019. Accessed 20 March 2023. <https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/about\/key-statistics.html>. 2019."},{"key":"10.1016\/j.radonc.2023.110057_b0010","unstructured":"Survival Rates for Malignant Mesothelioma. American Cancer Society. Last Revised: 2 March 2023. Accessed 20 March 2023. <https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/detection-diagnosis-staging\/survival-statistics.html>. 2023."},{"key":"10.1016\/j.radonc.2023.110057_b0015","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13014-015-0575-5","article-title":"Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy","volume":"10","author":"Thieke","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0025","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0030","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110057_b0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0045","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.33433","article-title":"Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110057_b0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41379-019-0352-3","article-title":"Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel","volume":"33","author":"Marchevsky","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.radonc.2023.110057_b0055","article-title":"A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma","volume":"4","author":"Rimner","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2023.110057_b0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fonc.2019.00961","article-title":"Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy","volume":"9","author":"Schroder","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2020.11.022","article-title":"Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma","volume":"152","author":"Ghirardelli","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110057_b0070","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110057_b0080","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.18632\/oncotarget.14858","article-title":"High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2023.110057_b0085","first-page":"267","article-title":"Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era","volume":"22","author":"Moding","year":"2016","journal-title":"Cancer J Jul-Aug"},{"key":"10.1016\/j.radonc.2023.110057_b0090","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0095","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol Sep-Oct"},{"key":"10.1016\/j.radonc.2023.110057_b0105","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2014.08.008","article-title":"Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy","volume":"90","author":"Modh","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110057_b0110","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/0284186X.2018.1481292","article-title":"Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC)","volume":"57","author":"von Reibnitz","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lungcan.2021.02.033","article-title":"Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy","volume":"157","author":"Barsky","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110057_b0120","doi-asserted-by":"crossref","unstructured":"Hanna GG, John T, Ball DL. Controversies in the role of radiotherapy in pleural mesothelioma. Transl Lung Cancer Res. Apr 2021;10(4):2079-2087. 10.21037\/tlcr-20-583.","DOI":"10.21037\/tlcr-20-583"},{"key":"10.1016\/j.radonc.2023.110057_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2019.03.023","article-title":"The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group","volume":"132","author":"MacRae","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110057_b0130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.prro.2020.02.007","article-title":"Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review","volume":"10","author":"Patel","year":"2020","journal-title":"Pract Radiat Oncol Nov-Dec"},{"key":"10.1016\/j.radonc.2023.110057_b0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0360-3016(98)00409-X","article-title":"Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura\u2013a single-institution experience with 189 patients","volume":"43","author":"de Graaf-Strukowska","year":"1999","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"10.1016\/j.radonc.2023.110057_b0140","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","volume":"14","author":"Gomez","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0145","article-title":"Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease","volume":"20(1):1210","author":"Collins","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.110057_b0150","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/0030-4220(93)90046-7","article-title":"Metastatic mesothelioma of the oral cavity. Report of two cases","volume":"76","author":"Kerpel","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.radonc.2023.110057_b0155","first-page":"16","article-title":"Multiple distant metastases in a case of malignant pleural mesothelioma","volume":"13","author":"Tertemiz","year":"2014","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.radonc.2023.110057_b0160","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0165","doi-asserted-by":"crossref","unstructured":"Alley EW, Katz SI, Cengel KA, Simone CB, 2nd. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res. Apr 2017;6(2):212-219. 10.21037\/tlcr.2017.04.01.","DOI":"10.21037\/tlcr.2017.04.01"},{"key":"10.1016\/j.radonc.2023.110057_b0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110057_b0175","unstructured":"Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME). Royal Marsden NHS Foundation Trust. Last Update Posted: 12 April 2021. Accessed 20 March 2023. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04166734>."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:26:09Z","timestamp":1759123569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":35,"alternative-id":["S0167814023093647"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110057","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110057"}}